Revenue
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Idexx Laboratories Inc (IDXX)
Price$516.62Cached quote
Net income
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.30B | $3.90B | $3.66B | $3.37B | $3.22B | $2.71B | $2.41B | $2.21B | $1.97B | $1.78B | $1.60B | $1.49B | $1.38B | $1.29B | $1.22B | $1.10B | $1.03B | $1.02B |
| Gross profit | $2.66B | $2.38B | $2.19B | $2.00B | $1.89B | $1.57B | $1.37B | $1.24B | $1.10B | $975.4M | $890.3M | $816.1M | $756.1M | $699.1M | $646.5M | $578.6M | $526.3M | $529.8M |
| Gross margin | 61.80% | 61.04% | 59.82% | 59.52% | 58.76% | 58.04% | 56.73% | 56.10% | 55.73% | 54.94% | 55.58% | 54.93% | 54.91% | 54.06% | 53.05% | 52.44% | 51.01% | 51.73% |
| Research & development | $251.2M | $219.8M | $191.0M | $254.8M | $161.0M | $141.2M | $133.2M | $117.9M | $109.2M | $101.1M | $99.7M | $98.3M | $88.0M | $82.0M | $76.0M | $68.6M | $65.1M | $70.7M |
| Operating expenses | $1.30B | $1.25B | $1.09B | $1.11B | $957.4M | $876.5M | $812.7M | $750.2M | $684.4M | $625.2M | $590.4M | $555.9M | $489.4M | $436.6M | $410.3M | $374.7M | $350.3M | $357.3M |
| Operating income | $1.36B | $1.13B | $1.10B | $898.8M | $932.0M | $694.5M | $552.8M | $491.3M | $413.0M | $350.2M | $299.9M | $260.3M | $266.8M | $262.6M | $236.2M | $203.9M | $176.0M | $172.5M |
| Operating margin | 31.60% | 28.95% | 29.97% | 26.69% | 28.99% | 25.66% | 22.97% | 22.20% | 20.98% | 19.73% | 18.72% | 17.52% | 19.37% | 20.30% | 19.38% | 18.48% | 17.06% | 16.84% |
| EBITDA | $1.51B | $1.26B | $1.21B | $1.01B | $1.04B | $790.5M | $640.9M | $574.5M | $496.2M | $428.5M | $368.9M | $319.1M | $321.4M | $315.0M | $284.4M | $249.8M | $225.7M | $220.4M |
| EBITDA margin | 34.97% | 32.28% | 33.11% | 30.01% | 32.24% | 29.21% | 26.63% | 25.96% | 25.20% | 24.13% | 23.03% | 21.48% | 23.34% | 24.35% | 23.34% | 22.64% | 21.88% | 21.53% |
| Net income | $1.06B | $887.9M | $845.0M | $679.1M | $744.8M | $581.8M | $427.7M | $377.0M | $263.1M | $222.0M | $192.1M | $181.9M | $187.8M | $178.3M | $161.8M | $141.3M | $122.2M | $116.2M |
| Net profit margin | 24.62% | 22.78% | 23.08% | 20.17% | 23.17% | 21.49% | 17.77% | 17.04% | 13.36% | 12.51% | 11.99% | 12.24% | 13.64% | 13.78% | 13.28% | 12.80% | 11.85% | 11.34% |
| Basic EPSper basic share | $13.17 | $10.77 | $10.17 | $8.12 | $8.74 | $6.82 | $4.97 | $4.34 | $3.00 | $2.47 | $2.07 | $1.82 | $1.77 | $1.62 | $1.43 | $1.23 | $1.04 | $0.97 |
| Diluted EPSper diluted share | $13.08 | $10.67 | $10.06 | $8.03 | $8.60 | $6.71 | $4.89 | $4.26 | $2.94 | $2.44 | $2.05 | $1.79 | $1.74 | $1.59 | $1.39 | $1.19 | $1.01 | $0.94 |
Owners
Reported shareholders
10.36%of listed shares
BlackRock, Inc.8.17M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 10.36%8.17M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 6.53%5.15M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 4.94%3.9M shares |
STATE STREET CORP | 4.75%3.75M shares |
Invesco Ltd. | 4.58%3.61M shares |
GEODE CAPITAL MANAGEMENT, LLC | 3.25%2.56M shares |
BAMCO INC /NY/ | 2.51%1.98M shares |
MORGAN STANLEY | 1.72%1.36M shares |
Bank of New York Mellon Corp | 1.51%1.19M shares |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.35%1.07M shares |
Fundsmith LLP | 1.29%1.02M shares |
BLAIR WILLIAM & CO/IL | 1.16%918.56K shares |
NORTHERN TRUST CORP | 1.16%918.14K shares |
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.16%911.49K shares |
FMR LLC | 1.04%822.64K shares |
AMERICAN CENTURY COMPANIES INC | 1.02%808.36K shares |
Capital Research Global Investors | 1.00%789.11K shares |
JPMORGAN CHASE & CO | 0.96%755.79K shares |
PRINCIPAL FINANCIAL GROUP INC | 0.94%743.25K shares |
GOLDMAN SACHS GROUP INC | 0.94%738.71K shares |
Percentages use 78.87M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 3, 2026Form 4 | Hunt NimrataExecutive Vice President | SellCommon Stock | 1.8K | $634.57 | $1.12M | 18.1K |
| Feb 26, 2026Form 4 | MAZELSKY JONATHAN JAYPresident and CEO | SellCommon Stock | 2.6K | $663.04 | $1.72M | 83.6K |
| Feb 26, 2026Form 4 | MAZELSKY JONATHAN JAYPresident and CEO | SellCommon Stock | 1.0K | $662.16 | $662.2K | 86.2K |
| Feb 26, 2026Form 4 | MAZELSKY JONATHAN JAYPresident and CEO | SellCommon Stock | 1.2K | $661.10 | $793.3K | 87.2K |
| Feb 26, 2026Form 4 | MAZELSKY JONATHAN JAYPresident and CEO | SellCommon Stock | 2.9K | $659.75 | $1.89M | 88.4K |